Contemporary Role of Avelumab First-line Maintenance in Advanced Urothelial Carcinoma with Consideration of the JAVELIN Bladder 100 Comprehensive Clinical Subgroup Analyses
Overview
Overview
Authors
Affiliations
Affiliations
Soon will be listed here.
References
1.
van der Heijden M, Sonpavde G, Powles T, Necchi A, Burotto M, Schenker M
. Nivolumab plus Gemcitabine-Cisplatin in Advanced Urothelial Carcinoma. N Engl J Med. 2023; 389(19):1778-1789.
DOI: 10.1056/NEJMoa2309863.
View
2.
Galsky M, Arranz Arija J, Bamias A, Davis I, De Santis M, Kikuchi E
. Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial. Lancet. 2020; 395(10236):1547-1557.
DOI: 10.1016/S0140-6736(20)30230-0.
View
3.
Zhou Z, Zhao Y, Chen S, Cui G, Fu W, Li S
. Cisplatin Promotes the Efficacy of Immune Checkpoint Inhibitor Therapy by Inducing Ferroptosis and Activating Neutrophils. Front Pharmacol. 2022; 13:870178.
PMC: 9240830.
DOI: 10.3389/fphar.2022.870178.
View
4.
Grivas P, Park S, Voog E, Caserta C, Gurney H, Bellmunt J
. Avelumab First-line Maintenance Therapy for Advanced Urothelial Carcinoma: Comprehensive Clinical Subgroup Analyses from the JAVELIN Bladder 100 Phase 3 Trial. Eur Urol. 2023; 84(1):95-108.
DOI: 10.1016/j.eururo.2023.03.030.
View
5.
Powles T, van der Heijden M, Castellano D, Galsky M, Loriot Y, Petrylak D
. Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol. 2020; 21(12):1574-1588.
DOI: 10.1016/S1470-2045(20)30541-6.
View